Daratumumab – breakthrough drug in multiple myeloma therapy
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2014, Vol 68, Issue
Abstract
Multiple myeloma (MM) remains incurable despite important recent advances in treatment. Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM. Early-stage clinical trials have found DARA to be safe and to have encouraging clinical activity as a single agent and in combination with lenalidomide in heavily pretreated, relapsed patients in whom other novel agents (such as bortezomib, thalidomide and lenalidomide) as well as stem cell transplant has already failed. This review discusses the preclinical and clinical development of DARA, its pathophysiological basis, and its prospects for future use in MM.
Authors and Affiliations
Artur Jurczyszyn, Agata Kosmaczewska, Aleksander B. Skotnicki
Keywords
Related Articles
- EP ID EP67528
- DOI -
- Views 134
- Downloads 0
Profil serologiczny chorych na twardzinę układową
β-glukuronidaza surowicy krwi jako potencjalny marker raka jelita grubego – badanie wstępne
Aging of prokaryotic organisms
Until recently it was thought that aging is a characteristic feature only of cells and organisms of eukaryotic origin. Recent studies on Caulobacter crescentus showed that their dimorphic life cycle associated with asymm...
Cytology screening tests and the incidence of cervical cancer in the Lower Silesia province in 2005-2014
Introduction: Cervical cancer is the sixth most common malignant cancer in Poland, whereas in most EU countries it has not been included in the top ten in many years. The aim of this paper was to evaluate the impact of s...
Pancreatic and gastric heterotopy in the gastrointestinal tract
Heterotopic or ectopic tissue is a congenital anomaly defined as the presence of the tissue outside its normal location. This tissue is usually discovered incidentally and may be asymptomatic or may present with non-spec...